Background Heart failure affects 1–2% of the population and is associated with elevated
morbidity and mortality. Cardiac arrhythmias are often a result of heart failure, but they can …

Objectives: This study sought to synthesize the available evidence on the use of the
wearable cardioverter-defibrillator (WCD). Background: Observational WCD studies for the …

Objectives To synthesise the available evidence of wearable cardioverter defibrillator (WCD)
therapy as an add-on measure to optimal medical therapy (OMT) or as a replacement of …

Abstract Background The prospective WEARIT-II-EUROPE registry aimed to assess the
value of the wearable cardioverter-defibrillator (WCD) prior to potential ICD implantation in …

The wearable cardioverter–defibrillator (WCD) is used in patients with newly diagnosed
heart failure and reduced ejection fraction (HFrEF). In addition to arrhythmic events, the …

Abstract Purpose of Review The wearable defibrillator (WCD) was shown to be safe and
effective in detecting and terminating ventricular tachyarrhythmias and therefore allows …

Introduction Wearable cardioverter-defibrillator (WCD) is a novel tool that may be of interest
in situations with atransient risk of sudden cardiac death. It offers a temporary and easy to …

ObjectivesTo assess the effectiveness, efficacy, and safety of a wearable cardioverter-
defibrillator (WCD) in adult persons with high risk for sudden cardiac arrest and for which an …

Arrhythmia-induced cardiomyopathy (AIC) is classified as a form of dilated cardiomyopathy
in which left ventricular systolic dysfunction (LVSD) is triggered by tachycardic or arrhythmic …

The introduction of wearable cardioverter defibrillators (WCD) provides a novel means of
protection in select patients at high risk for sudden cardiac death. The WCD can safely …